Wilms Tumor ? WT1, WTX Genes

Wilms Tumor is a pediatric kidney cancer predominantly driven by genetic alterations in the WT1 and WTX genes. Mutations in WT1 disrupt its tumor suppressor function, leading to abnormal cell proliferation and a predisposition to Wilms Tumor. WT1 mutations are found in roughly 5-20% of Wilms Tumor cases and may also cause developmental syndromes, including Denys-Drash and Frasier syndromes. WT1’s normal role includes regulating genes crucial for urogenital system differentiation, and its loss affects cellular growth control.

WTX acts as a tumor suppressor and is involved in the WNT/β-catenin signaling pathway. It promotes β-catenin degradation, preventing aberrant cellular proliferation. WTX is inactivated—typically by deletions or point mutations—in up to 30% of Wilms Tumors, and its mutations tend to be mutually exclusive with WT1 mutations.

Understanding these genetic drivers is crucial for diagnosis, risk assessment, and the development of targeted therapies for affected children.